Roche Holding stock rises as enicepatide delivers 15.5 percent weight loss

Roche Holding stock (ISIN CH0012032048) traded at CHF 371.44 on the SIX Swiss Exchange on September 22, 2026, up 1.25 percent, as the company reported Phase II enicepatide results. According to Roche on September 22, 2026, the highest 24 mg dose produced a mean weight loss of 15.5 percent after 48 weeks and reduced HbA1c by 2.65 percent.

Enicepatide posts two key results

The Phase II CT-388-104 study met both primary endpoints after 48 weeks, according to Roche. The 24 mg group achieved a 2.65 percent HbA1c reduction from a baseline of 8.1 percent, while 90 percent of patients reached an HbA1c level of 6.5 percent or lower.

The metabolic signal extended beyond glucose control. Roche reported that 62 percent of patients reached normoglycemia below 5.7 percent, and the 15.5 percent mean weight loss showed no plateau at week 48. The study included 447 adults with type 2 diabetes and overweight or obesity, giving the result a defined clinical base rather than a small exploratory sample.

Development now moves toward Phase III

Roche said on September 22, 2026, that two Phase III studies in chronic weight management, ENITH-1 and ENITH-2, are ongoing. The company also plans to start a Phase III glycemic-control program and cardiovascular outcomes trials in the first half of 2027, according to Roche.

The principal counter-factor is development risk: enicepatide remains investigational, and the current evidence comes from a Phase II study. Roche reported treatment discontinuation because of adverse events at 2.0 percent in the enicepatide arms versus 0.0 percent for placebo, while describing the safety profile as consistent with the incretin class.

Stock remains near its yearly high

Roche traded at CHF 371.44 on September 22, 2026, with a 52-week high of CHF 375.80 and a 52-week low of CHF 252.20. The latest level was 1.25 percent higher on the day and stood CHF 4.36 below the yearly high, leaving the clinical update priced against an already elevated range position.

For comparison, the September 21, 2026, SIX SX snapshot showed Roche at CHF 361.70, with 83,829 shares traded and a range of CHF 359.00 to CHF 361.70. The stock therefore advanced CHF 9.74 between that snapshot and the September 22 quotation, although the two observations have different intraday timestamps.

Roche Holding stock closes near CHF 372

Roche Holding stock stood at CHF 371.44 on the SIX Swiss Exchange on September 22, 2026, in CHF. The market value was CHF 344.458 billion as of September 21, 2026.

More news and analyses on Roche Holding stock